Skip to main content
SpringerLink
Log in

Biothérapies en rhumatologie pédiatrique

  • Chapter
Biothèrapies en rhumatologie

  • 257 Accesses

Résumé

L’introduction des biothérapies en rhumatologie pédiatrique a suivi de peu d’années les 1ers essais dans la polyarthrite rhumatoide de l’adulte. Ainsi, le récepteur soluble du TNF-α, etanercept, a été introduit en pédiatrie depuis une douzaine d’années aux états-Unis (1) et une dizaine d’années en Europe (2, 3). De manière encore plus remarquable, le canakinumab, l’anticorps monoclonal anti-IL-1, a fait l’objet d’études cliniques de manière concomitante chez l’adulte et l’enfant. L’effi cacité et la bonne tolérance de ce traitement dans des maladies rares à début pédiatrique que sont le syndrome de Muckle-Wells (4) et la forme systémique d’arthrite juvénile idiopathique (FS-AJI) (ou maladie de Still pédiatrique) a encouragé des essais plus récents dans des maladies de l’adulte aussi fréquentes que le diabète de type 2.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Lövell DJ, Giannini EH, Reiff A et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl I Med 342: 763–9

    Article  Google Scholar 

  2. Quartier P, Taupin P, Bourdeaut F et al. (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48:1093–101

    Article  PubMed  CAS  Google Scholar 

  3. Horneff G, Schmeling H, Biedermann T et al. (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638–44

    Article  PubMed  CAS  Google Scholar 

  4. Lachmann HI, Kone-Paut I, Kuemmerle-Deschner IB et al. (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl I Med 360:2416–25

    Article  CAS  Google Scholar 

  5. Petty RE, Southwood TR, Manners P et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31: 390–2

    PubMed  Google Scholar 

  6. Dinarello CA (2009) Interleukin-1beta and the autoinflammatory diseases. N Engl I Med 360:2467–70

    Article  CAS  Google Scholar 

  7. Wouters CH, Martin TM, Stichweh D et al. (2007) Infantile onset panniculitis with uveitis and systemic granulomatosis: a new clinicopathologic entity. J Pediatr 151: 707–9

    Article  PubMed  Google Scholar 

  8. TynjäläP, Kotaniemi K, Lindahl P et al. (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 47: 339–44

    Article  Google Scholar 

  9. Horneff G, De Bock F, Foeldvari I et al. (2008) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 68: 519–25

    Article  PubMed  Google Scholar 

  10. Lövell DJ, Reiff A, Ilowite NT et al. (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496–504

    Article  PubMed  Google Scholar 

  11. Lövell DJ, Ruperto N, Goodman S et al. (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359: 810–20

    Article  PubMed  Google Scholar 

  12. Marvillet I, Terrada C, Quartier P et al. (2009) Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine 76: 383–8

    Article  PubMed  Google Scholar 

  13. Pascual V, Allantaz F, Arce E et al. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. I Exp Med. 201:1479–86

    Article  CAS  Google Scholar 

  14. Lequerré T, Quartier P, Rosellini D et al. (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67: 302–8

    Article  PubMed  Google Scholar 

  15. Gattorno M, Piccini A, Lasigliè D étal. (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58:1505–15

    Article  PubMed  CAS  Google Scholar 

  16. Allantaz F, Chaussabel D, Stichweh D et al. (2007) Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 204:2131–44

    Article  PubMed  CAS  Google Scholar 

  17. Goldbach-Mansky R, Dailey NJ, Canna SW et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581–92

    Article  PubMed  CAS  Google Scholar 

  18. Picco P, Brisca G, Traverso F et al. (2009 ) Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 60: 264–8

    Article  PubMed  CAS  Google Scholar 

  19. Aksentijevich I, Masters SL, Ferguson PJ et al. (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360: 2426–37

    Article  PubMed  CAS  Google Scholar 

  20. Neven B, Marvillet I, Terrada C et al. (2010) Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease, chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62:258–67

    Article  PubMed  CAS  Google Scholar 

  21. Goldbach-Mansky R, Shroff SD, Wilson M. et al. (2008) Apilot study to evaluatethe safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58:2432–42

    Article  PubMed  CAS  Google Scholar 

  22. Hoffman HM, Throne ML, Amar NJ et al. (2008) Efficacy and safety of rUonacept (interleukin-1 Trap) in patients with cryopyrin-associatedperiodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443–52

    Article  PubMed  CAS  Google Scholar 

  23. Yokota S, Imagawa T, Mori M. et al. (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371: 998–1006

    Article  PubMed  CAS  Google Scholar 

  24. Ruperto N, Lovell DJ, Quartier P et al. (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383–91

    Article  PubMed  CAS  Google Scholar 

  25. Willems M, Haddad E, Niaudet P et al. (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148: 623–627

    Article  PubMed  CAS  Google Scholar 

  26. Nwobi O, Abitbol CL, Chandar J etal. (2008) Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23: 413–9

    Google Scholar 

  27. Podolskaya A, Stadermann M, Pilkington C et al. (2008) B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 93:401–6

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Quartier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Bader-Meunier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Mouy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Quartier, P., Bader-Meunier, B., Mouy, R. (2011). Biothérapies en rhumatologie pédiatrique. In: Biothèrapies en rhumatologie. Springer, Paris. https://doi.org/10.1007/978-2-8178-0124-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0124-7_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0123-0

  • Online ISBN: 978-2-8178-0124-7

Publish with us

Policies and ethics

Search

Navigation